Healthcare Industry News: Eli Lilly
News Release - May 19, 2014
Biocept Announces National Sales ForceOncology Sales Specialists to Deploy Blood-Based Cancer Diagnostics Into Physician Practices and Pharmaceutical Development Markets
SAN DIEGO, May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. (BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and Circulating Tumor Cells (CTCs), today announced the recruitment of a national sales team to support the commercialization of its OncoCEE(TM) services.
"We are extremely excited to have engaged such a high caliber sales force," said Michael Nall, President and CEO of Biocept. "Each member of our new team brings significant experience in oncology and pharmaceutical sales to Biocept. Our ability to recruit top talent and deploy OncoCEE(TM) into markets as varied as community oncology, academic research and pharmaceutical development is clear recognition of the unmet medical need for blood-based oncology diagnostics."
The newly-enlisted team is highly experienced and will be focused solely on oncology sales -- both to community oncologists, as well as to pharmaceutical companies that can use Biocept's products and services as potential companion diagnostics or to monitor clinical trial progress. Each representative possesses more than 15 years of oncology sales experience with companies such as Genentech, Eli Lilly, GE Healthcare, Clarient, Life Technologies and LabCorp, among others.
Raaj Trivedi, Biocept Vice President of Commercial Operations, stated, "The strategic hiring of a seasoned sales force is the first step in our commercial expansion. This infrastructure will enable the Company to focus on establishing a strong U.S. sales footprint in oncology diagnostics and also holds the potential for expansion into international markets. Each sales territory is strategically defined to promote our services to physicians and to patient support groups, providing sales coverage for the entire U.S. with territories based in Calif., Texas, Md., Fla., Tenn. and N.J. Additionally, by establishing a team focused on pharmaceutical services, we aim to increase our engagement with pharmaceutical companies and to participate in their diagnostic development activities and clinical trials."
About Biocept, Inc.
Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics company focused on providing information about patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BR(TM) test for breast cancer and plans to introduce CLIA-validated tests for lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms over the coming months.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the anticipated focus of our sales team on oncology sales, the anticipated establishment of our sales footprint, and our anticipated international expansion, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings, including without limitation the need to grow our business and our operations, our need for capital, and the effects of reimbursement limitations and other health care statutory and regulatory initiatives. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the Securities and Exchange Commission, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.